
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. has demonstrated a positive growth trajectory in its EsoGuard testing, with a sequential increase in the number of tests processed from 2,756 in Q2 to 2,841 in Q3, highlighting increasing market demand for its diagnostic services. The company's valuation is seen as attractive, as it appropriately reflects a balance of inherent risks while indicating substantial upside potential, further supported by an upward revision in the 12-month price target based on net present value analysis. Additionally, the anticipated growth of its newly commercialized products is expected to significantly contribute to revenues in 2025 and 2026, enhancing the overall positive financial outlook for PAVmed.
Bears say
PAVmed Inc. reported a pro forma net loss of $0.8 million for the latest quarter, indicating a continued struggle with profitability as it fell short of both its own and consensus earnings estimates. The decline in the number of EsoGuard tests processed, which decreased to 2,756 from 3,034 in the previous quarter, highlights potential challenges in demand for its diagnostic services. Additionally, the company faces numerous risks including liquidity concerns, regulatory hurdles, and market competition, which collectively contribute to a negative outlook on its financial performance and future growth prospects.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares